Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Parp Inhibitors for the Treatment of Ovarian Cancer

9 Mar 2018

Abstract excerpt

The standard of treatment for advanced ovarian cancer is represented by optimal surgical debulking preceded or followed by chemotherapeutic regimens including taxanes and platinum agents, possibly associated with bevacizumab and/or intraperitoneal therapy. Despite this comprehensive treatment strategy, almost 75% of patients relapse or progress and are therefore candidates for a second-line treatment, showing, at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Integrated Circuits and Semiconductor Failure Analysis
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29521233
DOI: 10.2174/1568009618666180308104646

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Parp Inhibitors for the Treatment of Ovarian CancerPMID 29521233Read ↗

Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.Semantic proximity Read ↗

PARP inhibitors: A new era of targeted therapy.Semantic proximity Read ↗

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current statusSemantic proximity Read ↗

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.Semantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”Semantic proximity Read ↗

PARP inhibitors in ovarian cancerSemantic proximity Read ↗

Perspectives on PARP Inhibitor Combinations for Ovarian CancerSemantic proximity Read ↗

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.Semantic proximity Read ↗

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancerSemantic proximity Read ↗

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancerSemantic proximity Read ↗

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targetingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.